New Zealand Adds Two Prostate Drugs To Coverage List
This article was originally published in PharmAsia News
Executive Summary
New Zealand's drug-management agency, Pharmac, has decided to cover drugs for treating a pair of prostate problems. Merck's Fintral (finasteride) and AstraZeneca's Bicalox (bicalutamide) are to be covered beginning Nov. 1 for advanced prostate cancer. Pharmac's medical director said the decision to include the drugs in its formicary was based on the fact some patients do not respond to other available drugs. He estimated 3,000 men could be treated with Fintral by 2011, 300 with Bicalox. (Click here for more